2025 Annual Meeting | Industry Thereapeutic Update from The Global CEO Initiative on Alzheimer's Disease: Blood-Based Biomarkers for Alzheimer’s Disease: A New Era in Diagnosis and Clinical Care

Date Saturday 04/05/25

Time 11:45 AM - 12:45 PM PDT Add To Calendar

Location San Diego Convention Center | 6CF

Session Format This program will be presented in-person only

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Director(s) Kavita Nair, PhD, FAAN

Topic(s) General Neurology, Aging, Dementia, and Behavioral Neurology

Learning Objectives Blood-based biomarkers are transforming the diagnosis and management of Alzheimer’s disease by providing a non-invasive, accessible, and cost-effective alternative to traditional diagnostic methods. This session will highlight the latest advancements in biomarker research, focusing on how high-performing blood tests are enabling earlier and more accurate detection of Alzheimer’s pathology. Attendees will gain insights into the practical application of these biomarkers in clinical settings, including their role in diagnosing cognitive impairment, guiding the use of treatments, and improving ongoing patient care and management. Experts will also address key challenges to widespread adoption, such as accessibility, integration into clinical workflows, and the need for clinician and patient education. As these tools gain momentum, they hold the potential to redefine the standard of care in neurology, enabling earlier intervention and improving outcomes for millions of patients worldwide.
This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2025 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

CME Available No CME available

Program Materials Program Evaluations

Event Timeline
11:45 AM - 12:45 PM PDT	Speaker	Industry Thereapeutic Update from The Global CEO Initiative on Alzheimer's Disease: Blood-Based Biomarkers for Alzheimer’s Disease: A New Era in Diagnosis and Clinical Care

Faculty Disclosures
Kavita Nair, PhD, FAAN	Dr. Nair has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bristol Meyers Squibb. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Nair has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for PhRMA Foundation. Dr. Nair has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Nair has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for MJH Lifesciences. Dr. Nair has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Anylam . Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Applied Patient Experience. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Esai. Dr. Nair has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for MHJ Life Sciences. Dr. Nair has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi-Genzyme. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for ICER. The institution of Dr. Nair has received research support from Genentech. The institution of Dr. Nair has received research support from Novartis. The institution of Dr. Nair has received research support from Genentech. The institution of Dr. Nair has received research support from Phrma Foundation. The institution of Dr. Nair has received research support from Bristol Meyers Squibb. The institution of Dr. Nair has received research support from Novartis. The institution of Dr. Nair has received research support from NINDS. The institution of Dr. Nair has received research support from Sanofi Genzyme. The institution of Dr. Nair has received research support from Kyverna Therapeutcis. Dr. Nair has a non-compensated relationship as a Board Member with Center for Improving Value in Healthcare that is relevant to AAN interests or activities.

��ɫ��

��ɫ��